{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:26:16Z","timestamp":1783664776238,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009287","name":"NSW Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B virus (HBV) care cascade characterisation is important for monitoring HBV elimination progress. This study evaluated care cascade and factors associated with HBV DNA testing and treatment in New South Wales, Australia. HBV care cascade were determined through linkage of HBV notifications (1993\u20132017) to Medicare and pharmaceutical benefits schemes (2010\u20132018). Timely HBV DNA testing was within 4\u2009weeks of HBV notification. Multivariate Cox proportional hazards regression evaluated factors associated with HBV DNA testing and treatment. Among 15,202 people with HBV notification, 10,479 (69%) were tested for HBV DNA. A total of 3179 (21%) initiated HBV treatment. HBV DNA testing was more likely among age \u226545\u2009years (adjusted hazard ratio [aHR] 1.07, 95% CI: 1.02, 1.12), hepatocellular carcinoma (HCC) (aHR 1.23, 95% CI: 1.01, 1.50), coinfection (aHR 1.61, 95% CI: 1.23, 2.09), later notification (2014\u20132017) (aHR 1.21, 95% CI: 1.16, 1.26) and less likely among females (aHR 0.95, 95% CI: 0.91, 0.99), history of alcohol use disorder (AUD) (aHR 0.77, 95% CI: 0.66, 0.89), HCV coinfection (aHR .62, 95% CI: 0.55, 0.70) and Indigenous peoples (aHR 0.84, 95% CI: 0.71, 0.98). HBV treatment was associated with age \u226545\u2009years (aHR 1.35, 95% CI: 1.24, 1.48), decompensated cirrhosis (aHR 2.07, 95% CI: 1.62, 2.65), HCC (aHR 2.96, 95% CI: 2.35, 3.74), HIV coinfection (aHR 4.27, 95% CI: 3.43, 5.31) and later notification (2014\u20132017) (aHR 1.37, 95% CI: 1.26, 1.47). HBV treatment was less likely among females (aHR 0.68, 95% CI: 0.63, 0.73) and Indigenous peoples (aHR 0.58, 95% CI: 0.42, 0.80). HBV DNA testing and treatment coverage have increased, but remain sub\u2010optimal among some key populations.<\/jats:p>","DOI":"10.1111\/jvh.13881","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T04:49:36Z","timestamp":1691556576000},"page":"926-938","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cascade of care among people with hepatitis B in New South Wales, Australia"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-1140","authenticated-orcid":false,"given":"Syed Hassan Bin Usman","family":"Shah","sequence":"first","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Valerio","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Matthews","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Alavi","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program (VHCRP) The Kirby Institute, UNSW  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00124-8"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.011"},{"key":"e_1_2_14_4_1","volume-title":"Interim Guidance for Country Validation of Viral Hepatitis Elimination","author":"World Health Organization","year":"2021"},{"key":"e_1_2_14_5_1","volume-title":"Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis","author":"World Health Organization","year":"2016"},{"key":"e_1_2_14_6_1","volume-title":"Global Hepatitis Report 2017: World Health Organization","author":"World Health Organization","year":"2017"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.216_12923"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14227"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anzjph.2022.100011"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_14_13_1","volume-title":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","author":"World Health Organization","year":"2015"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28280"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30270-X"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6728a2"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-6405.12345"},{"key":"e_1_2_14_19_1","volume-title":"Monitoring and Evaluation for Viral Hepatitis B and C: Recommended Indicators and Framework","author":"World Health Organization","year":"2016"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3110-0"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.014"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69374-4"},{"key":"e_1_2_14_23_1","unstructured":"The centre for health record linkage (CHeReL).How record linkage works: NSW Ministry of Health.2022.https:\/\/www.cherel.org.au\/how\u2010record\u2010linkage\u2010works"},{"key":"e_1_2_14_24_1","unstructured":"Australian Institute of Health and Welfare.Data linkage Canbera (ACT): Australian Institute of Health and Welfare.2022.https:\/\/www.aihw.gov.au\/our\u2010services\/data\u2010linkage"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51430"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.038"},{"issue":"17","key":"e_1_2_14_27_1","first-page":"1655","article-title":"Alcohol use in adults","volume":"368","author":"Friedmann PD","year":"2013","journal-title":"N Engl J Med"},{"key":"e_1_2_14_28_1","unstructured":"Population and Public Health Division.Improved reporting of Aboriginal and Torres Strait Islander peoples on population datasets in New South Wales using record linkage\u2013a feasibility study Sydney: NSW Ministry of Health.https:\/\/www.health.nsw.gov.au\/hsnsw\/Pages\/atsi\u2010data\u2010linkage\u2010report.aspx"},{"key":"e_1_2_14_29_1","volume-title":"Third national hepatitis B strategy","author":"Department of Health Australian Government","year":"2018"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51114"},{"key":"e_1_2_14_31_1","volume-title":"Hepatitis B Mapping Project: Estimates of Geographic Diversity in Chronic Hepatitis B Prevalance, Diagnosis, Monitoring and Treatment: National Report 2016","author":"MacLachlan J","year":"2018"},{"key":"e_1_2_14_32_1","volume-title":"Viral Hepatitis Mapping Project: Geographic Diversity in Chronic Hepatitis B and C Prevalence, Management and Treatment National Report 2020","author":"MacLachlan JH","year":"2022"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30899"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13791"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.005"},{"key":"e_1_2_14_36_1","volume-title":"Monitoring Hepatitis C Treatment Uptake in Australia (Issue 12)","author":"The Kirby Institute","year":"2022"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3982-4"},{"key":"e_1_2_14_38_1","volume-title":"Pharmaceutical Benefits Scheme (PBS) New Options for HIV and Hepatitis B Medicine Supply","author":"Australian Government","year":"2015"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32162"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14071496"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-016-0316-8"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1476-0"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.029"},{"key":"e_1_2_14_44_1","volume-title":"NSW Hepatitis B Strategy 2023\u20132026","author":"NSW Health","year":"2023"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23461"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00106"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0377"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100552"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1021905"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i16.2269"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-18"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:07:53Z","timestamp":1700136473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/jvh.13881"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13881","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"2023-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}